Introduction A case report on the inclusion of a patient expert on a pharmaceutical company’s external Bioethics Advisory Panel. The patient expert was proposed to the existing panel so...
Transcription Of course, my name’s Ross Carroll. I’m the Public Affairs Director for the UK and Ireland for UCB pharma. Within that role, I’m responsible for government affairs, for...
A recording of the EUPATI webinar entitled 'Creating Trainings with the EUPATI Toolbox'. In the first part of the webinar John Lenehan will present the usage statistics of the...
Part of a different era, activist or patient advocate? I started in patient advocacy in 1991. We didn’t call it patient advocacy back then. We got buckets of glue...
Paediatric medicine development requires careful planning and decision making. Legislation in the EU mandates that paediatric medicine development should occur early in the medicine development process.
Medicine adherence (also known as ‘patient adherence’ or ‘compliance’) is how well patients follow doctors’ instructions about the timing, frequency, and dosage when taking a medicine.
HTA bodies carry out clinical effectiveness assessments, in which new technologies are compared with the standard of care and other existing treatments.
During lead generation, many molecules are tested for target interaction. These may then need to be altered, or optimised, in order to improve their effect on the target.